heptapeptide is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-07-09. Where a claim depends on a specific study, the study is described rather than over-claimed.
The C-terminal Pro-Gly-Pro extension is not incidental. Proline-rich tails are known to resist several common peptidases, and the published literature attributes the longer half-life of Semax, relative to unmodified ACTH fragments, to this feature. The modification also removes the melanocyte-stimulating and corticosteroidogenic activity that characterizes longer ACTH-derived sequences. Because the molecule is small and hydrophilic, it is typically formulated as an aqueous solution for intranasal or parenteral delivery. Acetylation or amidation at the termini appears in closely related research peptides and shifts the mass by a fixed increment.
Reported pharmacological work centers on neurotrophic signaling, including changes in BDNF and NGF expression in hippocampal tissue in animal models. Human data come largely from studies conducted in Russia, and how well those results generalize to other populations remains an open question. Regulatory status differs sharply by jurisdiction: Semax is a registered prescription medicine in Russia, while it holds no approved marketing status in the United States or the European Union. Outside such jurisdictions it is generally handled as a research chemical, which affects both documentation and quality expectations.
Terminology around the compound varies by source. It appears in catalogues and papers as Semax, as the heptapeptide ACTH(4-7)-Pro-Gly-Pro, and under various alphanumeric laboratory codes used by individual suppliers. These names refer to the same sequence but may imply different salt forms, purity grades, or counter-ions. Peptide databases usually list the free base mass, while product descriptions sometimes report acetate or trifluoroacetate salts with a different formula weight. Because naming conventions for research peptides are not standardised across vendors, checking the declared sequence and measured mass is more reliable than relying on a trade name alone.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. Its design combines the ACTH(4-7) core fragment with a C-terminal Pro-Gly-Pro extension, a modification intended to improve stability and prolong activity. The molecule is hydrophilic, carries no lipid chains or glycosylation, and has a theoretical mass just over 810 daltons in its free form. All seven residues are proteinogenic amino acids, so no non-natural building blocks appear in the backbone. A free N-terminal methionine and C-terminal proline define the unmodified parent peptide.
The compound was developed during the 1980s at the Institute of Molecular Genetics in Moscow as part of research on fragments of adrenocorticotropic hormone. Early work examined short ACTH-derived sequences that retained neurotrophic effects while lacking the endocrine activity of the full hormone. Semax entered clinical use in Russia during the 1990s, where it received registration for several neurological indications. Outside that region it remained primarily a laboratory research material rather than an approved therapeutic. English-language literature on it grew more slowly and frequently cited the original Russian studies.
| Property | Value | Notes |
|---|---|---|
| Molecular weight | ~813.9 Da (free heptapeptide) | N-acetylated form is about 42 Da heavier |
| Residue count | 7 (heptapeptide) | Four residues from ACTH(4-10), three added |
| Appearance | White to off-white powder | Usually supplied lyophilized |
| Solubility class | Freely soluble in water | Also dissolves in DMSO and polar organic solvents |
| Related parent fragment | ACTH(4-10) | Parent motif is Met-Glu-His-Phe |
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It is described in the literature as an analogue of the ACTH(4–10) fragment, a short N-terminal portion of adrenocorticotropic hormone that retains some neurotropic activity without the full hormonal effects of the parent peptide. The molecule carries a methionine residue at the N-terminus and two proline residues near the C-terminus, features that shape both its interactions with receptor systems and its chemical stability. The free peptide corresponds to the formula C37H51N9O10S and a molecular mass near 813.9 Da.
The compound was developed in the 1980s at the Institute of Molecular Genetics in Moscow, where it emerged from research on short ACTH fragments and their effects on the central nervous system. Russian pharmaceutical listings describe it as a nootropic and neuroprotective agent, most often formulated as nasal drops. It is not a marketed medicine in the United States or the European Union, and no pharmacopoeial monograph covers it. Consequently, most published clinical experience with the substance originates from a small number of research centres, mainly in Russia and neighbouring countries.
Regulatory status varies sharply by country. Semax is registered for medical use in Russia, where it appears in formularies as a nasal solution, and it also holds registration in a small number of neighbouring states. It has no approval from the United States Food and Drug Administration or the European Medicines Agency, and it is not a scheduled controlled substance in most jurisdictions. Elsewhere it circulates mainly as laboratory material, so purity documentation comes from suppliers rather than from a national pharmacopoeia.
Semax is a synthetic peptide created in the Soviet Union during the early 1980s by researchers working in Moscow. It was built from the short adrenocorticotropic hormone fragment known as ACTH(4-10), and the chain was then extended with three additional amino acids. The resulting molecule was named semax and entered clinical use in Russia in 1994. It is generally described as a nootropic and neuroprotective agent rather than as a hormone analogue.
== Musical style == Chuquimamani-Condori's music is notable for drawing from an eclectic and wide variety of influences, including cumbia, and Andean music like huayno and tarqueada, as well as American genres like crunk, metal, ambient, R&B and minimalism. However, their eclecticism is owed to their understanding and incorporation of Aymara ontology in their music, specifically the concepts of taypi and ch'ixi. As a way of summing up their stylistic intent, they have used the tags prog and folk to describe their music. During the time of the making of their album American Drift, they were living in rural Virginia and being inspired by the expansive local geographical features around the area, described as "wild Southern surroundings", in the area, one of which was the Shenandoah Mountain. They previously made journeys around it, with one inspiring track two of American Drift, 'Petrichrist'. They are heavily inspired by varying forms of cultural music and the interesting sound design that often accompanies them, although their upbringing and roots in music that have influenced their show their presence. In an interview, they remarked that "the older I get, the uglier I want my music to feel, to be".
== Background == Glutathione plays a central role in cellular redox balance, detoxification, and immune regulation. Its synthesis depends on the availability of several amino acid substrates, of which cysteine is typically the rate-limiting precursor under physiological conditions. Free L-cysteine is chemically unstable and readily oxidized in the gastrointestinal tract, which can limit its effectiveness when administered directly as a supplement. For this reason, a variety of cysteine-delivery strategies have been explored, including N-acetylcysteine (NAC) and other cysteine prodrugs. D-Ribose-L-cysteine was developed as an alternative cysteine-delivery compound intended to improve cysteine stability and intracellular availability for glutathione synthesis.
== Discovery and development == Tralokinumab was discovered by Cambridge Antibody Technology scientists using protein optimization based on Ribosome Display. They used the extensive data sets from ribosome display to patent protect CAT-354 in a world-first of sequence-activity-relationship claims. In 2004, clinical development of CAT-354 was initiated with this first study completing in 2005. On 21 July 2011, MedImmune LLC initiated a Phase IIb, randomized, double-blind study to evaluate the efficacy of tralokinumab in adults with asthma. In 2016, MedImmune and AstraZeneca started developing tralokinumab for asthma (Phase III) and atopic dermatitis (Phase IIb) while clinical development for moderate-to-severe ulcerative colitis and idiopathic pulmonary fibrosis (IPF) have been discontinued. In July of that year AstraZeneca licensed tralokinumab to Leo Pharma for skin diseases. A phase IIb study of tralokinumab found that treatment was associated with early and sustained improvements in atopic dermatitis symptoms and tralokinumab had an acceptable safety and tolerability profile, thereby providing evidence for targeting IL-13 in patients with atopic dermatitis. In June 2017, Leo Pharma started phase III clinical trials with tralokinumab in atopic dermatitis.
Starfish may be preyed on by conspecifics, sea anemones, other starfish species, tritons, crabs, fish, gulls, and sea otters. Their first lines of defence are the saponins present in their body walls, which have unpleasant flavours. Some starfish such as Astropecten polyacanthus also include powerful toxins such as tetrodotoxin, while the slime star can ooze out large quantities of repellent mucus. The crown-of-thorns starfish possesses sharp spines, toxins and bright warning colours.
== Modern colloquial usage == The term "culottes" in more recent French describes women's underpants, an article of clothing that has little or no relation to the historical culottes, but now also refers to apparent skirts that are actually split with two legs. The term sans-culottes has been used colloquially to mean not wearing underpants.
Sources: en.wikipedia.org
== Collaborations == In 2013, La Colombe partnered with the Clinton Foundation to found the Haiti Coffee Academy. The organization's stated aim is to improve coffee growers’ livelihoods in Haiti through training programs for smallholder farmers, a demonstration farm and nursery, and efforts to strengthen the supply chain for both local and export markets for Haitian coffee. In 2016, La Colombe collaborated with Yards Brewing Company, also in the Philadelphia area, to produce a coffee stout to be served in local Shake Shack branches. Also in 2016, the company collaborated with the Icelandic brewer Einstök and again with Yards on Snorri's Awakening, a coffee pale ale. In 2021, the company collaborated with Whole Foods Market to open new stores in New York City and Austin.
=== By country === List of submarine operators Australia – Collins-class submarine Bangladesh – Submarines of the Bangladesh Navy China – Submarines of the People's Liberation Army Navy France – Submarines in the French Navy, List of submarines of the French Navy, List of French submarine classes and types Germany – List of U-boats of Germany India – Submarines of the Indian Navy Israel – Dolphin-class submarine Japan – Imperial Japanese Navy submarines, List of combatant ship classes of the Japan Maritime Self-Defense Force § SS : Submarine The Netherlands – List of submarines of the Netherlands Pakistan – List of active Pakistan Navy ships § Submarines Poland – List of ships of the Polish Navy § Submarine fleet Romania – Romanian submarines of World War II Russia – List of Soviet and Russian submarine classes, Future Russian submarines Soviet Union – List of ships of the Soviet Navy § Submarines Spain – List of submarines of the Spanish Navy Singapore – Republic of Singapore Navy § Submarines Turkey – List of submarines of the Turkish Navy United Kingdom – List of submarines of the Royal Navy, List of submarine classes of the Royal Navy United States – Submarines in the US Navy, List of submarines of the US Navy, List of US submarine classes, Naval Submarine Medical Research Laboratory
Here, a, b, and c are lattice constants in picometers, No is the space group number, and Z is the number of formula units per unit cell; fcc stands for the face-centered cubic symmetry. Density was not measured directly but calculated from the lattice parameters.
== Clinical significance == Furin is one of the proteases responsible for the proteolytic cleavage of HIV envelope polyprotein precursor gp160 to gp120 and gp41 prior to viral assembly. This protease is also thought to play a role in tumor progression. The use of alternate polyadenylation sites has been found for the FURIN gene. Furin is enriched in the Golgi apparatus, where it functions to cleave other proteins into their mature/active forms. Furin cleaves proteins just downstream of a basic amino acid target sequence (canonically, Arg-X-(Arg/Lys) -Arg'). In addition to processing cellular precursor proteins, furin is also used by a number of pathogens. For example, the envelope proteins of viruses such as HIV, influenza, dengue fever, several filoviruses including ebola and marburg virus, and the spike protein of SARS-CoV-2, must be cleaved by furin or furin-like proteases to become fully functional. When SARS-CoV-2 virus is being synthesized in an infected cell, furin or furin-like proteases cleave the spike protein into two portions (S1 and S2), which remain associated. Anthrax toxin, Pseudomonas exotoxin, and papillomaviruses must be processed by furin during their initial entry into host cells. Inhibitors of furin are under consideration as therapeutic agents for treating anthrax infection. Furin is regulated by cholesterol and substrate presentation. When cholesterol is high, furin traffics to GM1 lipid rafts. When cholesterol is low, furin traffics to the disordered region. This is speculated to contribute to cholesterol and age dependent priming of SARS-CoV.
Sources: en.wikipedia.org
The sequence is Met-Glu-His-Phe-Pro-Gly-Pro, a seven-residue peptide. The first four residues correspond to the ACTH(4-10) fragment, and Pro-Gly-Pro is added at the C-terminus. N-acetylated versions also appear in the literature and differ in mass.
Semax is a synthetic analog of the ACTH(4-10) fragment rather than a copy of the full hormone. Truncation plus the added tail removes the steroidogenic portion of ACTH. That distinction explains why it is studied for nervous-system effects instead of adrenal stimulation.
It is registered as a prescription product in Russia and has been used there clinically, chiefly by the intranasal route. No approval exists in the United States or the European Union. Availability elsewhere typically falls under research-chemical distribution, with varying purity documentation.
It is a synthetic seven-amino-acid peptide built from the ACTH(4-7) sequence plus a Pro-Gly-Pro tail. It belongs to the family of short ACTH fragments studied for nervous-system effects. Its backbone contains only standard amino acids.